IND granted for FAP targeting therapeutic in SOFIE partnership
Dulles, VA – January 17, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
SOFIE granted IND for 18F-FAPI in Phase 2 study
Dulles, VA – November 29, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
FAPI Clinical Development Updates
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
ICPO Theranostics FAP Summit (virtual)
November 5, 2022 […]
Focus on FAPI Newsletter – Q4 2022
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
We are excited to launch our FAPI newsletter […]
SOFIE submits IND for [18F]-FAPI-74 in Phase 2 study of Gastrointestinal Cancers
Dulles, VA – October 31, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
First Patient Imaged in SOFIE’s FAPI Phase II Trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged […]









